• Tue news: Pfizer explores sale of hospital drugs unit. FDA declines full approval of Ocaliva. AZ better than expected Q3 results. Pfizer, Lilly telehealth platforms draw scrutiny. 23andMe cutting lays off 40%. See more on our front page

QIAGEN is a sinking ship

Anonymous

Guest
They are a great Life Science company, providing tools for sample prep to insight.
But they don't have a complete solution for most anything. The MDx market, especially in the United States is asking for more.